New study tracks Real-World safety of targeted lung cancer drug
NCT ID NCT03375242
First seen Apr 10, 2026 · Last updated May 06, 2026 · Updated 6 times
Summary
This study looks at how safe and effective XALKORI is for people with a specific kind of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. Researchers will track side effects and measure how well the drug shrinks tumors. About 97 participants are being followed to gather real-world information on the drug's risks and benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.